Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Implementation of a Multipronged Intervention to Improvement Inpatient Sickle Cell Disease Care

Daniela Anderson, Valerie G. Press, Kenneth S. Cohen, Nabil Abou Baker

Blood (2023) 142 (Supplement 1): 5062.

https://doi.org/10.1182/blood-2023-189612

Published: 2023

Journal Articles

Prospective Multi-Center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas

Kirk Cahill, James Godfrey, Chadi Nabhan, Theodore G. Karrison, Jessica Robertson, Justin Kline, Kenneth S. Cohen, Michael R. Bishop, Walter M. Stadler, Reem Karmali, Parameswaran Venugopal, Seo-Hyun Kim, Aaron P. Rapoport, Sonali M. Smith

Blood (2022) 140 (Supplement 1): 6594–6595.

https://doi.org/10.1182/blood-2022-168444

Published: 2022

Journal Articles

Racial Variation in ITP Prevalence and Rate of Chronic Disease Suggests Biological Differences

Lauryn S. Walker, Taylor Olmsted Kim, MD, Amanda Bell Grimes, MD, Susan Kirk, PA-C, Audrey S. Cohen, Abinaya Arulselvan, Scott E. Wenderfer, MD, Michele P. Lambert, MD, Jenny M. Despotovic, DO, MS

Blood (2019) 134 (Supplement_1): 387.

https://doi.org/10.1182/blood-2019-130418

Published: 2019

Journal Articles

Phase II Study of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309

Justin Kline, MD, Aaron P. Rapoport, MD, Adam M. Petrich, MD, Kenneth S. Cohen, MD, Sachdev P. Thomas, MD, Sreenivasa Nattam, MD, Krishna Rao, MD, Bethany Sleckman, MD, Walter Stadler, MD, Theodore Karrison, PhD, Sonali M. Smith, MD

Blood (2016) 128 (22): 4147.

https://doi.org/10.1182/blood.V128.22.4147.4147

Published: 2016

Journal Articles

Selective MEK Inhibition with AZD-6244 (selumetinib) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A University of Chicago Phase II Consortium Trial

Natalie Galanina, MD, Sonali M. Smith, MD, Chuanhong Liao, PhD, Adam M. Petrich, MD, Bernadette Libao, Ron Gartenhaus, MD, Jason R Westin, MD, Kenneth S. Cohen, MD, James Knost, MD, Walter Stadler, MD, Austin Doyle, MD, Theodore Karrison, PhD, Leo I. Gordon, MD, Andrew M Evens, DO, MS

Blood (2015) 126 (23): 3990.

https://doi.org/10.1182/blood.V126.23.3990.3990

Published: 2015

Journal Articles

Circulating CD34 + progenitor cell frequency is associated with clinical and genetic factors

Kenneth S. Cohen, Susan Cheng, Martin G. Larson, L. Adrienne Cupples, Elizabeth L. McCabe, Ying A. Wang, Julius S. Ngwa, Roderick P. Martin, Rachael J. Klein, Basma Hashmi, Yin Ge, Christopher J. O'Donnell, Ramachandran S. Vasan, Stanley Y. Shaw, Thomas J. Wang

Blood (2013) 121 (8): e50–e56.

https://doi.org/10.1182/blood-2012-05-424846

Published: 2013

Includes: Supplemental data

Journal Articles

Siltuximab Treatment Increases Hemoglobin (Hb) Levels: Preliminary Results From a Prospective Phase 1 Study In Refractory Solid Tumors

R. Kurzrock, E. Angévin, S. Cohen, J. Van Laethem, B. Rijnbeek, J. Vermeulen, B. Tromp, W. Li, M. Reddy, M. Cornfeld, J. Tabernero

Blood (2010) 116 (21): 5150.

https://doi.org/10.1182/blood.V116.21.5150.5150

Published: 2010

Journal Articles

CD34+ Circulating Progenitor Cell Frequency Is Highly Heritable

Kenneth S. Cohen, MD, Susan Cheng, MD, Martin G. Larson, ScD, L. Adrienne Cupples, PhD, Elizabeth L. McCabe, MS, Ying A. Wang, PhD, Roderick P. Martin, ALB, Rachael J. Klein, MS, Basma Hashmi, BS, Christopher J. O'Donnell, MD, Vasan S. Ramachandran, MD, Stanley Y. Shaw, MD, PhD, Thomas J. Wang, MD

Blood (2010) 116 (21): 4309.

https://doi.org/10.1182/blood.V116.21.4309.4309

Published: 2010

Journal Articles

Alemtuzumab-Containing Allogeneic Hematopoietic Cell Transplant (HCT) for Relapsed Lymphomas: Prognostic Factors and Outcome.

Vaishalee P. Kenkre, MD, Sarah Horowitz, Sonali M. Smith, MD, Andrew Artz, MD, MS, Kenneth S. Cohen, MD, Lucy A Godley, M.D., Ph.D., Justin Kline, M.D., Wendy Stock, MD, Koen van Besien, MD

Blood (2009) 114 (22): 2247.

https://doi.org/10.1182/blood.V114.22.2247.2247

Published: 2009

Journal Articles

Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels

Patrick Au, Laurence M. Daheron, Dan G. Duda, Kenneth S. Cohen, James A. Tyrrell, Ryan M. Lanning, Dai Fukumura, David T. Scadden, Rakesh K. Jain

Blood (2008) 111 (3): 1302–1305.

https://doi.org/10.1182/blood-2007-06-094318

Published: 2008

Includes: Multimedia, Supplemental data

Journal Articles

p90RSK2 as a Therapeutic Target in Treatment of FGFR3-Expressing t(4;14) Multiple Myeloma.

Sumin Kang, PhD, Shaozhong Dong, PhD, Tinglei Gu, PhD, Ailan Guo, PhD, Michael S. Cohen, PhD, Sagar Lonial, MD, PhD, Petet Leif Bergsagel, MD, PhD, Jack Taunton, PhD, Roberto D. Polakiewicz, PhD, Jing Chen, PhD

Blood (2007) 110 (11): 253.

https://doi.org/10.1182/blood.V110.11.253.253

Published: 2007

Journal Articles

Oxidative Stress Induces Changes and Shedding of Membrane Phospholipids from Thalassemic RBCs - A NMR Study.

Eitan Fibach, PhD, Inna Freikman, M.Sc, Johnny Amer, Ph.D, Jack S. Cohen, Ph.D, Israel Ringel, Ph.D

Blood (2007) 110 (11): 1782.

https://doi.org/10.1182/blood.V110.11.1782.1782

Published: 2007

Journal Articles

FGFR3 Activates RSK2 To Mediate Hematopoietic Transformation through Both Tyrosine Phosphorylation of RSK2 and Activation of the MEK/ERK Pathway.

Sumin Kang, PhD, Shaozhong Dong, PhD, Ting-lei Gu, PhD, Michael S. Cohen, Sagar Lonial, MD, H. Jean Khoury, PhD, D. Gary Gilliland, MD, PhD, Jack Taunton, PhD, Roberto D. Polakiewicz, PhD, Jing Chen, PhD

Blood (2006) 108 (11): 514.

https://doi.org/10.1182/blood.V108.11.514.514

Published: 2006

Journal Articles

Evidence for incorporation of bone marrow–derived endothelial cells into perfused blood vessels in tumors

Dan G. Duda, Kenneth S. Cohen, Sergey V. Kozin, Jean Y. Perentes, Dai Fukumura, David T. Scadden, Rakesh K. Jain

Blood (2006) 107 (7): 2774–2776.

https://doi.org/10.1182/blood-2005-08-3210

Published: 2006

Includes: Supplemental data

Journal Articles

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain

Blood (2006) 107 (1): 293–300.

https://doi.org/10.1182/blood-2005-06-2469

Published: 2006

Journal Articles

Autologous Bone Marrow Transplant after Failed Peripheral Blood Stem Cell Mobilization Does Not Adversely Affect Engraftment or Transplant Related Toxicity.

B. Rioux-Masse, MD, J. Roy, MD, R. Belanger, MD, D.C. Roy, MD, L. Busque, MD, D. Fish, MD, G. Sauvageau, MD, T. Kiss, MD, S. Cohen, MD

Blood (2005) 106 (11): 2736.

https://doi.org/10.1182/blood.V106.11.2736.2736

Published: 2005

Journal Articles

Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine Consolidation in Newly Diagnosed Patients with AML.

Richard M. Stone, Thomas Fischer, Ronald Paquette, Gary Schiller, Charles A. Schiffer, Gerhard Ehninger, Jorge Cortes, Hagop Kantarjian, Daniel A. DeAngelo, Richard Yu, Lei Zhang, Pamela S. Cohen, Yanfeng Wang, Penny Phillips, Francis Giles

Blood (2005) 106 (11): 404.

https://doi.org/10.1182/blood.V106.11.404.404

Published: 2005

Journal Articles

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation

Jason Gotlib, Caroline Berubé, Joseph D. Growney, Ching-Cheng Chen, Tracy I. George, Christopher Williams, Tomohiro Kajiguchi, Jia Ruan, Stan L. Lilleberg, Jeffrey A. Durocher, Jack H. Lichy, Yanfeng Wang, Pamela S. Cohen, Daniel A. Arber, Michael C. Heinrich, Len Neckers, Stephen J. Galli, D. Gary Gilliland, Steven E. Coutré

Blood (2005) 106 (8): 2865–2870.

https://doi.org/10.1182/blood-2005-04-1568

Published: 2005

Journal Articles

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)

Thomas Kindler, Frank Breitenbuecher, Stefan Kasper, Eli Estey, Francis Giles, Eric Feldman, Gerhard Ehninger, Gary Schiller, Virginia Klimek, Stephen D. Nimer, Alois Gratwohl, Chuna Ram Choudhary, Constan Mueller-Tidow, Hubert Serve, Harald Gschaidmeier, Pamela S. Cohen, Christoph Huber, Thomas Fischer

Blood (2005) 105 (1): 335–340.

https://doi.org/10.1182/blood-2004-02-0660

Published: 2005

Journal Articles

Phase 1 Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Concomitant Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine (HDAra-C) Consolidation in Newly Diagnosed Patients with AML.

Francis Giles, C. Schiffer, H. Kantarjian, T. Fischer, R. Paquette, D. M. Pelov, D. J. Resta, P. S. Cohen, Y. F. Wang, R. Stone

Blood (2004) 104 (11): 262.

https://doi.org/10.1182/blood.V104.11.262.262

Published: 2004

NARROW

Implementation of a Multipronged Intervention to Improvement Inpatient Sickle Cell Disease Care

Prospective Multi-Center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas

Racial Variation in ITP Prevalence and Rate of Chronic Disease Suggests Biological Differences

Phase II Study of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309

Selective MEK Inhibition with AZD-6244 (selumetinib) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A University of Chicago Phase II Consortium Trial

Circulating CD34 + progenitor cell frequency is associated with clinical and genetic factors

Siltuximab Treatment Increases Hemoglobin (Hb) Levels: Preliminary Results From a Prospective Phase 1 Study In Refractory Solid Tumors

CD34+ Circulating Progenitor Cell Frequency Is Highly Heritable

Alemtuzumab-Containing Allogeneic Hematopoietic Cell Transplant (HCT) for Relapsed Lymphomas: Prognostic Factors and Outcome.

Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels

p90RSK2 as a Therapeutic Target in Treatment of FGFR3-Expressing t(4;14) Multiple Myeloma.

Oxidative Stress Induces Changes and Shedding of Membrane Phospholipids from Thalassemic RBCs - A NMR Study.

FGFR3 Activates RSK2 To Mediate Hematopoietic Transformation through Both Tyrosine Phosphorylation of RSK2 and Activation of the MEK/ERK Pathway.

Evidence for incorporation of bone marrow–derived endothelial cells into perfused blood vessels in tumors

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain

Autologous Bone Marrow Transplant after Failed Peripheral Blood Stem Cell Mobilization Does Not Adversely Affect Engraftment or Transplant Related Toxicity.

Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine Consolidation in Newly Diagnosed Patients with AML.

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)

Phase 1 Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Concomitant Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine (HDAra-C) Consolidation in Newly Diagnosed Patients with AML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only